Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 2,061 | $46.35 | $95,527.35 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 6 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,792 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 1,020 | $46.54 | $47,470.80 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,853 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · derivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,667 Underlying: Common Stock · 18,333 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 8,131 | $46.54 | $378,416.74 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,832,403 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 Underlying: Common Stock · 4,166 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 2,056 | $46.54 | $95,686.24 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,428 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · derivative · entry 8 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Tax withholdingCommon Stock | 998 | $46.54 | $46,446.92 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · nonDerivative · entry 4 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,001 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · derivative · entry 9 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 Underlying: Common Stock · 2,833 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,257 | $46.54 | $58,500.78 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · nonDerivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,411 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · nonDerivative · entry 3 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,167 Underlying: Common Stock · 4,583 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,033 | $46.54 | $94,615.82 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,859 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · derivative · entry 8 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 294 | $46.54 | $13,682.76 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,578 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · derivative · entry 6 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,448 | $46.54 | $67,389.92 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · nonDerivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,418.99 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · nonDerivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,866.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · derivative · entry 7 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,819 Underlying: Common Stock · 1,272 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 581 | $46.48 | $27,004.88 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,350 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002380 · doc4.xml · derivative · entry 7 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,970 Underlying: Common Stock · 990 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 456 | $46.48 | $21,194.88 |
DisclosureSEC source: 0001225208-23-002380 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,535 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002380 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionRestricted Stock Units · Derivative | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · derivative · entry 9 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,910 Underlying: Common Stock · 2,970 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 1,409 | $46.79 | $65,927.11 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,540 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 909 | $46.48 | $42,250.32 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,949 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002378 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,795 Underlying: Common Stock · 16,264 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,214 | $46.48 | $335,306.72 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,822,201 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002377 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,829,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,880 Underlying: Common Stock · 3,960 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,806 | $46.48 | $83,942.88 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,318 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002376 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · derivative · entry 7 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,153 Underlying: Common Stock · 2,050 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Tax withholdingCommon Stock | 910 | $46.48 | $42,296.80 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,749 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002372 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · derivative · entry 8 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,638 Underlying: Common Stock · 2,545 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,129 | $46.48 | $52,475.92 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,835 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002371 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,729 Underlying: Common Stock · 4,243 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,250 | $46.48 | $58,100.00 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,309 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002369 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · derivative · entry 7 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516 Underlying: Common Stock · 1,838 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.